Thrivent Financial for Lutherans raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,187,446 shares of the biopharmaceutical company's stock after acquiring an additional 28,090 shares during the period. Thrivent Financial for Lutherans owned approximately 0.18% of Gilead Sciences worth $183,396,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at $25,328,000. Legal & General Group Plc increased its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after acquiring an additional 93,068 shares during the last quarter. IRON Financial LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth $830,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock worth $19,630,000 after buying an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock worth $15,668,000 after buying an additional 119,909 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have commented on GILD shares. Oppenheimer lifted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Evercore ISI raised shares of Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $93.86.
Check Out Our Latest Research Report on GILD
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,947 shares of company stock valued at $4,968,674 over the last 90 days. Insiders own 0.16% of the company's stock.
Gilead Sciences Stock Down 4.0 %
Shares of NASDAQ GILD traded down $3.71 during midday trading on Friday, reaching $88.40. 11,454,518 shares of the company's stock traded hands, compared to its average volume of 6,971,457. The company has a quick ratio of 0.82, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock's 50 day simple moving average is $86.68 and its 200-day simple moving average is $76.11. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a market cap of $110.17 billion, a price-to-earnings ratio of 982.22, a P/E/G ratio of 2.72 and a beta of 0.17.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the firm earned $2.29 earnings per share. The company's quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. Gilead Sciences's payout ratio is 3,422.22%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
